The Hygiology Post ®

“Geron Reports Imetelstat Oral Presentation at European Hematology Association Congress GlobeNewswire•June 18, 2018″ (https://finance.yahoo.com/news/geron-reports-imetelstat-oral-presentation-104500446.html; obtained on 6-18-2018). Here is an excerpt: “ ‘This encore presentation of data from the first 32 patients in Part 1 of IMerge reiterates the encouraging results that prompted the expansion of enrollment of Part 1 to a refined population of lower risk MDS patients who are naïve to lenalidomide and HMAs and who lacked del(5q). We are pleased that there are multiple patients that have been on treatment for over two years,’ ” said John A. Scarlett, M.D., Geron’s President and Chief Executive Officer. “ ‘We look forward to data from the additional patients enrolled earlier this year in the expanded Part 1 of IMerge, as well as Janssen’s decision related to the continued development of imetelstat, which is expected by the end of the third quarter.’ ”   

The Geron Website also has slides from the Imetelstat Oral Presentation, “Imetelstat in RBC Transfusion-Dependent (TD) Lower Risk MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agents (ESA) (IMerge): Updated Efficacy and Safety” by “Fenaux P, et al. EHA 2018”   (https://www.geron.com/file.cfm/53/docs/Imetelstat-IMergePart1-EHA-2018.pdf; obtained on 6-18-2018).

The Author is a shareholder of Geron.